SEARCH CONTACT US

ACCESSIBILITY

24/7

Headlines

CyberArk, not SentinelOne, was always the goal, says Palo Alto CEO

Palo Alto CEO on $25B CyberArk deal: “This is the lowest our stock will be for the next five years”

CyberArk’s $25B exit enriches global funds, not Israelis

Check Point not for sale, says CEO as Palo Alto buys CyberArk for $25B

Buzz

Most popular

Daily

Weekly

1

Palo Alto closing on over $20 billion acquisition of CyberArk

2

Wiz finds major security flaw in Base44, one month after Wix acquisition

3

Palo Alto to acquire CyberArk for $25B in landmark cybersecurity deal

4

Intel’s global overhaul: What the memo didn’t say

5

Intel veterans raise $40 million to scale AI surveillance platform

Urology

5 stories about Urology

Avner Geva Avi Eftel Vensica

Vensica Therapeutics raises $16 million for its urology treatment platform

01.11.21|James Spiro

The biopharma company’s needle-free platform can improve patient experience, resolve needle-related issues, and make procedures easier

מנכ"ל מדיטייט עידו קילמניק עם ונסה מלכה סמנכ"לית מדיטייט

Israel’s Medi-Tate acquired by Japanese powerhouse Olympus Corporation for $300 million

26.02.21|Meir Orbach

The Israeli manufacturer of non-surgical solutions for BPH had previously raised $37 million from private investors

Johnson & Johnson Subsidiary Janssen Partners With Sustained Drug Release Company UroGen

The two companies will collaborate on the research of a “therapeutic area of mutual interest”

Sustained Drug Release Company UroGen Aiming to Raise $150 Million on Nasdaq

24.01.19|Lilach Baumer

Goldman Sachs & Co. LLC, JP Morgan, and Jefferies are the joint bookrunners for the offering

Vensica Medical Device

Overactive Bladder Treatment Startup Raises $2 Million

01.10.17|Lilach Baumer

Israel-based Vensica Medical developed an ultrasound-based device for needle-free delivery of Botox to the bladder